fashion -WSS

fashion

author：entertainment 2025-09-27 10:04:05 - browse：4

SAN DIEGO — One of the toughest subtypes of acute leukemia involves a genetic alteration in the KMT2A gene. Many cancers with this genetic alteration end up relapsing or don’t respond to treatment, but new data presented at the annual American Society of Hematology meeting offer hope of a new targeted therapy for these patients.

The study, called the Phase 2 Augment-101 trial, tested Syndax’s revumenib in patients with relapsed or refractory leukemia with these KMT2A genetic rearrangements. Overall, about 63% of the patients responded to the treatment, with many able to receive a potentially curative stem cell transplant later on, which is often the ultimate goal for patients with relapsed or refractory patients, said Ibrahim Aldoss, a hematologist-oncologist at City of Hope and the study’s presenter, in an interview.

“KMT2A-rearranged diseases represent 10% of all leukemia. They can be exceptionally hard to treat,” Aldoss said. “The median overall survival remains low with current available treatment. Right now there’s no targeted therapy for KMT2A-rearranged disease. We’re really excited about revumenib as it targets the mutation, and we’re seeing encouraging outcomes.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： How Vertex's cystic fibrosis drug is changing patients' lives

WSS

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

It's been 20 years since Dolly the sheep. Where's my clone?

How Vertex's cystic fibrosis drug is changing patients' lives

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Three trends to watch in biotech in 2024

In Spain, a hospital brews its own CAR

explore

fashion

explore

ChatGPT in medicine: STAT answers readers' burning questions

Hospitals owned by private equity see complications spike 25%

ChatGPT in medicine: STAT answers readers' burning questions

Can sheer will power keep patients alive in their dying hours?

ChatGPT in medicine: STAT answers readers' burning questions

Ukraine and a new approach to mental health in war

Hepatitis C has a cure — but many Americans still lack access to it

Senate HELP committee spars over health care workforce policies

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Why are Kaiser Permanente staff considering a strike?

leisure time

Changes to biosimilar regulatory framework must prioritize patients

Senate HELP committee spars over health care workforce policies

Biotech stock slump in 2023: awaiting the turnaround

Why are Kaiser Permanente staff considering a strike?

How AI helped researchers track recovery from depression

Experts study whether long Covid risk adds up with each reinfection

focus

entertainment

hotspot

leisure time